Yüklüyor......
Concizumab: a novel anti-TFPI therapeutic for hemophilia
Concizumab is a novel subcutaneous prophylactic therapy for hemophilia. It is a hemostatic rebalancing agent that binds to the Kunitz-2 domain of tissue factor pathway inhibitor (TFPI), one of the molecules that contributes to downregulation of coagulation thereby preventing TFPI from binding to and...
Kaydedildi:
| Yayımlandı: | Blood Adv |
|---|---|
| Yazar: | |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Society of Hematology
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7805331/ https://ncbi.nlm.nih.gov/pubmed/33570646 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001140 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|